Abstract: Objective The aim of this study was to observe the efficacy of liraglutide and atorvastatin calcium combination in the treatment of patients with nonalcoholic fatty liver diseases (NAFLD) with abnormal glucolipid metabolism. Methods 86 patients with NAFLD and abnormal glucolipid metabolism were enrolled in our hospital between January 2020 and December 2022, and were randomly divided into control (n=43) and observation group (n=43). The patients in both groups were given liraglutide treatment and those in the observation were treated by liraglutide and atorvastatin calcium combination for 12 weeks. The blood biochemical indicators, the liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) of liber were routinely detected. The visceral adiposity index (VAI) and the lipid accumulation product index (LAP) were calculated. Results At the end of 12 week of treatment, serum alanine aminotransferase, gamma-glutamyltransferase, LSM and CAP in the observation group were (32.8±4.9)U/L, (32.7±5.4)U/L, (5.0±0.9)kPa and (245.7±18.2)dB/m, all significantly lower than [(36.4±4.2)U/L,(39.0±5.1)U/L,(6.0±0.8)kPa and (268.9±19.1)dB/m, respectively, P<0.05] in the control; the VAI and LAP were (102.2±9.1) and (55.7±7.0), both significantly lower than [(118.3±10.5) and (62.0±6.7), respectively, P<0.05] in the control; serum total cholestero, triglyceride and low-density lipoprotein cholesterol levels were(4.8±0.8)mmol/L,(1.6±0.3)mmol/L and (2.7±0.4)mmol/L, all much lower than [(5.5±0.9)mmol/L, (2.8±0.3)mmol/L and (4.1±0.6)mmol/L, respectively, P<0.05], while serum high-density lipoprotein cholesterol level was (1.3±0.3)mmol/L, much higher than [(1.1±0.2)mmol/L, P<0.05] in the control group. Conclusion The administration of liraglutide and atorvastatin calcium combination in the treatment of patients with NAFLD with abnormal glucolipid metabolism could modulate the disordered glucolipid metabolism, alleviate the liver steatosis, and reduce the visceral fat accumulation, and the long-term efficacy needs further observation.

Key words: Nonalcoholic fatty liver diseases, Liraglutide, Atorvastatin, Visceral adiposity index, Lipid accumulation index, Therapy